Osivax has announced that all participants have completed their final visit in the Phase 2a clinical booster trial (NCT06582277) evaluating OVX836, Osivax’ broad-spectrum influenza A vaccine candidate.
Enterome SA presented new positive data from its ongoing Phase 1/2 “AUDREY” trial of its OncoMimics immunotherapy, EO4010, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
OptymEdge – part of the Emmes Group – have unveiled an enhancement to its ophthalmology services with the launch of the "clinical research industry’s first technology platform" dedicated solely to ophthalmology trials.
Moleculin Biotech, a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, has announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application.
Isarna Therapeutics presented final positive results from its Phase II BETTER trial at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting on 6th May.
Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy Breztri Aerosphere met all primary endpoints.
Lineage Cell Therapeutics, a clinical-stage biotechnology company, has announced that the Company has initiated the DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for Spinal Cord Injury: Evaluation of a Novel Device) clinical study.
CluePoints, provider of statistical and AI-driven software solutions, has been named as a finalist in the ‘Innovative Clinical Trial Solutions’ category at the 2025 Citeline Awards.
Phastar, a specialist biometrics & data science Contract Research Organisation (CRO), has been shortlisted in the ‘CRO Partnership of the Year’ category at the 2025 Citeline Awards for its collaboration with Medicines Development for Global Health.
Teckro has introduced its new Patient Data Return feature, providing patients with seamless access to their medical reports while giving sponsors greater oversight into engagement levels.
Johnson & Johnson has announced new icotrokinra (JNJ2113) data from its comprehensive Phase 3 clinical programme and the start of the first head-to-head study in plaque psoriasis (Pso) seeking to demonstrate the superiority of an oral pill.
Milan Libánský, marketing specialist at Quinta-Analytica, discusses anaemia, a serious medical condition affecting millions of people worldwide, characterised by a lack of healthy red blood cells to carry adequate oxygen to the body's tissues.
